Partner Investment Management L.P. Has $142,000 Stake in Accuray Incorporated (ARAY)
Partner Investment Management L.P. trimmed its stake in Accuray Incorporated (NASDAQ:ARAY) by 25.4% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 31,513 shares of the medical equipment provider’s stock after selling 10,755 shares during the quarter. Partner Investment Management L.P.’s holdings in Accuray were worth $142,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ARAY. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Accuray by 3,259.1% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,162,567 shares of the medical equipment provider’s stock worth $9,732,000 after acquiring an additional 2,098,187 shares during the last quarter. BlackRock Inc. raised its holdings in shares of Accuray by 8.9% in the second quarter. BlackRock Inc. now owns 8,807,077 shares of the medical equipment provider’s stock worth $36,110,000 after acquiring an additional 716,406 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of Accuray by 8.6% in the third quarter. Renaissance Technologies LLC now owns 5,312,623 shares of the medical equipment provider’s stock worth $23,907,000 after acquiring an additional 422,023 shares during the last quarter. Assenagon Asset Management S.A. acquired a new position in shares of Accuray in the third quarter worth $1,668,000. Finally, JPMorgan Chase & Co. raised its holdings in shares of Accuray by 1,329.4% in the third quarter. JPMorgan Chase & Co. now owns 324,279 shares of the medical equipment provider’s stock worth $1,459,000 after acquiring an additional 301,593 shares during the last quarter. 84.28% of the stock is owned by institutional investors.
In other Accuray news, CFO Shigeyuki Hamamatsu sold 8,762 shares of the business’s stock in a transaction dated Tuesday, October 2nd. The stock was sold at an average price of $4.48, for a total transaction of $39,253.76. Following the completion of the sale, the chief financial officer now owns 116,238 shares of the company’s stock, valued at $520,746.24. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Joshua Levine purchased 25,000 shares of the stock in a transaction on Monday, November 5th. The shares were purchased at an average cost of $4.75 per share, with a total value of $118,750.00. Following the transaction, the chief executive officer now owns 1,356,036 shares of the company’s stock, valued at approximately $6,441,171. The disclosure for this purchase can be found here. In the last ninety days, insiders sold 48,378 shares of company stock valued at $218,502. Company insiders own 3.40% of the company’s stock.
Accuray (NASDAQ:ARAY) last announced its quarterly earnings data on Tuesday, October 30th. The medical equipment provider reported ($0.11) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.09) by ($0.02). The business had revenue of $95.83 million during the quarter, compared to analysts’ expectations of $95.10 million. Accuray had a negative net margin of 5.79% and a negative return on equity of 42.24%. During the same period in the prior year, the firm earned ($0.11) EPS. On average, research analysts anticipate that Accuray Incorporated will post -0.14 earnings per share for the current fiscal year.
A number of brokerages have recently commented on ARAY. Jefferies Financial Group reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Accuray in a research report on Friday, August 17th. Citigroup raised Accuray from a “sell” rating to a “neutral” rating and lifted their price objective for the company from $3.50 to $3.90 in a research report on Thursday, November 1st. BTIG Research reaffirmed a “hold” rating on shares of Accuray in a research report on Wednesday, August 22nd. Finally, BidaskClub downgraded Accuray from a “sell” rating to a “strong sell” rating in a research report on Friday, August 17th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the company’s stock. Accuray currently has an average rating of “Hold” and a consensus target price of $5.63.
Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body.
Read More: Put Option
Want to see what other hedge funds are holding ARAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Accuray Incorporated (NASDAQ:ARAY).
Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.